Fate Therapeutics Inc (NASDAQ:FATE) currently has a daily average trading volume of 3.23M but it saw 2459806 shares traded in last market. With a market cap of 152.62M USD, the company’s current market price of $1.34 came rising about 1.52 while comparing to the previous closing price of $1.32. In past 52 weeks, the stock remained buoying in the range of price level as high as $8.83 and as low as $1.04. In the recent trading on the day, stock has struck highest price mark of $1.28 while lowest mark touched by it was $1.37.
Taking a look at 20-day trading activity of Fate Therapeutics Inc (FATE) gives us an average price of $1.5445, while its current price level is -84.82% below from 52-week high level whereas it is 28.85% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $2.0175 while that of 200 days or SMA-200 reads an average of $3.3879. A closer look into the stock’s movement over the week reveals that its volatility is standing at 6.78% during that period while stretching the period over a month that increases to 9.30%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 35.55 which implies that the stock is in neutral territory.
Piper Sandler upgraded its recommendation for the stock as a “Overweight” from “Neutral” on June 17, 2024 while assigning a price target range of $4-$6. Wells Fargo issued its recommendations for the stock as it resumed the price target for the stock is $6.
Over the week, FATE’s stock price is moving 6.77% up while it is -20.47% when we observe its performance for the past one month. Year-to-date it is -18.79% down and over the past year, the stock is showing a downside performance of -70.42%.
Currently, Fate Therapeutics Inc’s total number of outstanding shares is 113.88M with 2.28% of that held by the insiders while 100.27% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -39.22% and return on equity (ROE) at -46.59%. Stock’s beta reads 2.02. Stock has a price to book (P/B) ratio of 0.42 while price to sale or P/S ratio amounts to 11.35. Its return on asset (ROA) is -34.32% on average.
